Tisotumab vedotin FDA Approval Status
FDA Approved: No
Generic name: tisotumab vedotin
Company: Genmab A/S and Seagen Inc.
Treatment for: Cervical Cancer
Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) in development for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Development Timeline for tisotumab vedotin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.